Poonawalla wished the country and Prime Minister Narendra Modi success for the vaccination programme.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
Covishield vaccine production won't be hit due to the fire, Serum Institute of India Chief Executive Officer Adar Poonawalla said. The Manjari facility is where the Covishield vaccine used in the nationwide inoculation drive against the pandemic is made.
Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection.
Serum's CEO, Adar Poonwalla, accompanied Pawar.
COVAX, 'the global COVID vaccine equity scheme', has so far delivered 65 million doses to 124 countries and economies but it is dependent on countries and manufacturers honouring their commitments.
If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval.
In a joint statement posted on their respective twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.
'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.
It is not yet clear if Diageo Plc is looking to sell its complete stake in RCB.
Poonawalla, during an interaction with Odisha Chief Minister Naveen Patnaik through a video conference, expressed optimism that the COVID-19 vaccine could be ready by October-November this year and the next phase of the trial can start in mid-August in India. According to a press note released by the CMO, Poonawalla has informed that the Oxford University vaccine has shown promising results in the first phase trial.
One consortium is led by Manipal Hospitals' Dr Ranjan Pai along with US private equity firm KKR and Singapore investment major Temasek. The other is a combine of Swedish private equity firm EQT and Premji Invest, the investment office backed by Wipro founder Azim Premji.
The Serum Institute of India has stockpiled 40 mn-50 mn doses and is adding more every week. Most of these will come to India.
The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.
Poonawalla has been getting threats from various groups regarding the COVID-19 vaccine supplies.
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
Billionaire David Blitzer, co-founder of Harris Blitzer Sports & Entertainment, is conducting due diligence on Royal Challengers Bengaluru and Rajasthan Royals.
Pharma tycoon Adar Poonawalla has emerged as a potential suitor for the Indian Premier League franchise Royal Challengers Bengaluru, sparking fresh speculation around a possible change in ownership of one of the league's most high-profile teams.
'The challenge will be making sure its efficacy is high.' 'If a vaccine is only 50 to 60 per cent efficient, it's a double-edged sword.'
There are a number of trial sites across both Mumbai and Pune that we have shortlisted, as these cities have many hotspots, which will help us understand the efficacy of the vaccine, the company's chief executive Adar Poonawalla said.
The Pune-based company's chief executive Adar Poonawalla said the company, which is the largest vaccine maker in the world, is putting $200 million at risk by manufacturing nearly 300 million doses before the final nod to launch the vaccine in market, which is expected at best by the end of the year.
'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'
Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.
Poonawalla noted that reducing the timeframe would give "real relief" to the people who want to travel abroad.
An FIR was launched against some unidentified persons for cheating the SII for more than Rs 1 crore, said the officials on Sunday.
'We have just scratched the surface because cricket has been around for the longest time.'
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
The development comes after requests for indemnity and exemption from bridging trials have been made by Pfizer and Moderna to the Indian government.
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
SII executive director Suresh Jadhav on Friday alleged that the government began inoculating people from multiple age groups without taking into account the available stock of vaccines and the WHO guidelines.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
'Once DCGI will give us the permission to restart the trials in India, we will resume the trials,' Serum Institute of India (SII) said in a statement.
Businessmen from all over the world attended Radhika Merchant and Anant Ambani's wedding at the Jio World Convention Centre, Bandra Kurla Complex, north west Mumbai, on Friday, July 12, 2024.
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.
'I understand some people are comfortable getting a Covishield shot as their third dose.'
This will be an upfront payment for the vaccine doses that these two companies will supply to the government.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances